Merck & Co.
2000 Galloping Hill Road
About Merck & Co.
About our Company
We aspire to be the premier research-intensive biopharmaceutical company in the world. Innovation and scientific excellence are at the core of what we do in pursuit of our mission to save and improve lives. Together, we invent for a more hopeful future.
Who we are
Our company, Merck (known as MSD outside of the U.S. and Canada), is a global health care leader with a diversified portfolio of prescription medicines, vaccines, and animal health products. For more than 125 years we have been inventing for life. Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases like HIV and Ebola, and emerging animal diseases.
We hire the most brilliant minds because inventing for life depends on our work. Our dedicated employees come from an array of backgrounds and do many different things --from research and development and business technology to marketing and pharmaceutical sales. Yet each of us knows our work matters.
At Merck, you'll find rewarding opportunities, diverse experiences, and an unwavering commitment to ethics and integrity. You'll collaborate with talented colleagues who share your sense of purpose. Our company will empower you to innovate, explore, and develop your full potential in our possibility-rich environment. Join our team and help us invent, impact, and inspire every day.
3297 articles with Merck & Co.
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
Malawi becomes the second country in sub-Saharan Africa to eliminate lymphatic filariasis (elephantiasis)
The World Health Organization announced in this week's WHO Weekly Epidemiological Record that Malawi has been validated to have eliminated lymphatic filariasis as a public health problem.
Third-Quarter 2020 Worldwide Sales Were $12.6 Billion, an Increase of 1%; Excluding the Impact from Foreign Exchange, Sales Grew 2%
10/26/2020It was another busy week for clinical trial updates and news. Here’s a look.
Grants Will Be Administered through the MECTIZAN® Donation Program and Will Support Precautionary Measures Required to Prevent the Spread of SARS-CoV-2 During Mass Drug Administration Programs for These Two Diseases KENILWORTH, N.J.--( BUSINESS WIRE )-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN® Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO)
Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020
Data from More Than 50 Clinical and Epidemiological Abstracts Across Vaccines, HIV, Antibiotics and Antimicrobials Show the Breadth of the Company’s Commitment to Addressing the Threat of Infectious Diseases
Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
In PNEU-PATH (V114-016) and PNEU-DAY (V114-017), V114 Met Primary Immunogenicity Objectives and Elicited A Strong Immune Response for All 15 Serotypes Included in the Vaccine, Including 22F and 33F - Serotypes Unique to V114
Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine.
New data presented at the IASLC 2020 North America Conference on Lung Cancer shows a combination of Keytruda with other medications has a positive impact on non-small cell lung cancer.
The U.S. Food and Drug Administration has several PDUFA dates for the rest of October, although two of them were already approved. Here’s a look.
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Adult Patients With Relapsed or Refractory cHL After Frontline Therapy
Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment for Patients with Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial
The pharma giant is currently the only manufacturer of the bladder cancer treatment for the U.S. and Europe.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued its 2019/2020 Corporate Responsibility Report . The report highlights the company’s performance and progress in its four corporate responsibility priority areas of Access to Health, Employees, Environmental Sustainability and Ethics & Val
MerckManuals.com calls on patients and professionals to show their commitment to trusted, reliable medical knowledge in worldwide day of action
Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
Company Also Presenting Phase 1/1b Results for MK-8507, a New Investigational Once-Weekly Oral HIV Agent; Company Advances MK-8507 to Phase 2
Intec Pharma Ltd. announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA.
Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Roger M. Perlmutter will be retiring as Executive Vice President and President, Merck Research Laboratories (MRL). Dr. Perlmutter will be succeeded by Dr. Dean Y. Li, effective Jan. 1, 2021. Dr. Perlmutter will remain as a non-executive director, MRL through June 30, 2021 to facilitate a seamless transition. “Since rejoini
Merck announced that Roger M. Perlmutter, the company’s executive vice president and president of Merck Research Laboratories, was retiring effective January 1, 2021. He will be succeeded by Dean Y. Li.
Researchers Will Present Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination with Doravirine, and Phase 1/1b Data for MK-8507, an Investigational NNRTI for the Treatment of HIV-1 Infection